An Oncologist's Letter to Santa: Bring Me Drugs!
Authors: Tempero M PMID: 30545986 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Letter to the Editor: Could Immunogenicity of Kaposi Sarcoma Be More Linked to Viral Antigens Than to the Tumor Mutational Burden?
Authors: Delyon J, Arangalage D, Baroudjian B, Lebbe C, Brohl AS, Saller J PMID: 30545987 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

In Memoriam: Arti Hurria, MD.
Authors: McKoy JM PMID: 30545988 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib.
We report on a 71-year-old woman with a large advanced gastric GIST near the gastroesophageal junction initially involving the pancreas, spleen, adrenal, and aortic wall. The tumor harbored a KIT exon 11 deletion mutation in codon 558, which predicts a favorable response to imatinib. After 6 months of neoadjuvant imatinib therapy, the tumor was downstaged to allow partial gastric resection without the need for total gastrectomy reconstruction. The patient underwent partial gastrectomy, distal pancreatectomy, and splenectomy, and histologic examination showed a margin-negative resection with a near-pCR, with
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.
Authors: Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA Abstract The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the pan...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.
Conclusions: In an effort to expand understanding of the role of primary sidedness in clinical response to anti-EGFR therapy, we identified sidedness and tumor bulk as potential predictive biomarkers of clinical response in late-line mCRC. Future prospective studies of EGFR targeting should consider tumor bulk in addition to molecular profiling in the identification of populations most likely to achieve meaningful clinical benefit. PMID: 30545991 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Delays in Diagnosis and Treatment of Breast Cancer: A Safety-Net Population Profile.
Authors: Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E Abstract Background: Timely detection and treatment of breast cancer is important in optimizing survival and minimizing recurrence. Given disparities in breast cancer outcomes based on socioeconomic status, we examined time to diagnosis and treatment in a safety-net hospital. Methods: We conducted a retrospective review of all patients with breast cancer diagnosed between July 1, 2010, and June 30, 2012 (N=120). We limited our analytic sample to patients with nonrecurrent, primary stage 0-III breast cancer (N=105) and determined intervals from pres...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Authors: Niraula S, Nugent Z Abstract Background: FDA approvals do not consider cost, but they set the tone for regulatory approvals worldwide, including in countries with universal healthcare where cost-effectiveness, utility, and adoption feasibility are considered rigorously. Methods: Data from the pan-Canadian Oncology Drug Review (pCODR), a national drug review system that makes evidence-based funding recommendations to Canada's provinces and territories, were collected. Our objectives were to assess (1) temporal trends in cost and efficacy of drugs reviewed, (2) correlations among magnitude of benefits, cost,...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
Authors: Mokdad AA, Minter RM, Yopp AC, Porembka MR, Wang SC, Zhu H, Augustine MM, Mansour JC, Choti MA, Polanco PM Abstract Background: Preoperative therapy is being increasingly used in the treatment of resectable pancreatic cancer. Because there are only limited data on the optimal preoperative regimen, we compared overall survival (OS) between preoperative chemotherapy (CT) and preoperative chemoradiotherapy (CRT) in resectable pancreatic adenocarcinoma. Patients and Methods: Patients receiving preoperative therapy and resection for clinical T1-3N0-1M0 adenocarcinoma of the pancreas were identified in the Natio...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Na ïve Prostate Cancer.
This study aimed to determine whether cumulative toxicity comprising all-grade AEs is more associated with QoL than cumulative toxicity comprising high-grade AEs only, and whether patient-reported cumulative toxicity is more associated with QoL than clinician-reported cumulative toxicity. Methods: Patients with metastatic castration-naïve prostate cancer participating in the phase III GETUG-AFU 15 trial completed questionnaires on AEs (at 3 and 6 months) and QoL (at baseline and 3 and 6 months). Clinicians reported AEs during clinical visits. Cumulative toxicity scores were calculated for clinicians and patients in 3 ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Variation in Integrated Head and Neck Cancer Care: Impact of Patient and Hospital Characteristics.
Conclusions: Although the quality registration was only recently launched, it already visualizes hospital variation in current care. Four determinants were found to be influential: tumor stage, performance status, tumor site, and volume. More data are needed to assure stable results for use in quality improvement. PMID: 30545996 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Authors: Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H Abstract Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
This article reviews existing data on cytoreduction, evaluating hydroxyurea, interferons, and ruxolitinib in ET and PV. This review evaluates whether evidence supports a more liberal strategy of cytoreduction for all patients with ET and PV. PMID: 30545998 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
Authors: Weinberg BA PMID: 30545999 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Oncology Research Program.
Authors: PMID: 30546000 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Reviewer Page.
Authors: PMID: 30546001 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 15, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer.
This article reviews current endocrine treatment strategies and recent and ongoing studies of combination therapies in metastatic hormone receptor-positive, HER2-negative breast cancer. PMID: 30538108 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 13, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

I'm Conflicted. Are You?
Authors: Tempero M PMID: 30442729 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series.
This report provides additional insight into the heterogeneous patterns of disease response to anti-PD-1 therapy, highlighting the adrenal gland as a potential sanctuary site for this immunotherapy. These cases display the potential benefit of early surgical resection in this scenario and the pitfalls of delaying referral to a surgeon for assessment of operative intervention. PMID: 30442730 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.
Authors: Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh AM Abstract Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline str...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
Authors: Parsons BM, Uprety D, Smith AL, Borgert AJ, Dietrich LL Abstract Background: Despite the paucity of evidence supporting chemotherapy in the treatment of node-negative, HER2-positive breast cancer measuring
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Impact of a Clinical Decision Support System on Guideline Adherence of Surveillance Recommendations for Colonoscopy After Polypectomy.
Authors: Magrath M, Yang E, Ahn C, Mayorga CA, Gopal P, Murphy CC, Gupta S, Agrawal D, Halm EA, Borton EK, Skinner CS, Singal AG Abstract Background: Surveillance colonoscopy is required in patients with polyps due to an elevated colorectal cancer (CRC) risk; however, studies suggest substantial overuse and underuse of surveillance colonoscopy. The goal of this study was to characterize guideline adherence of surveillance recommendations after implementation of an electronic medical record (EMR)-based Colonoscopy Pathology Reporting and Clinical Decision Support System (CoRS). Methods: We performed a retrospective ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Conclusions: This systematic review suggests that implementation of these tests in clinical practice could effectuate personalized treatment of PCa. Further clinical and economic evaluation studies of long-term PCa outcomes are warranted to provide further guidance. PMID: 30442734 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
Conclusions: California Latino men diagnosed with localized high-risk PCa are at increased risk for undertreatment. The observed treatment disparity is largely explained by sociodemographic factors, suggesting it may be ameliorated through targeted outreach, such as that aimed at younger and underinsured Latino men. PMID: 30442735 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Authors: Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R Abstract The NCCN Guidelines for Breast Cancer Screening and Diagnosis have been developed to facilitate clinical decision making. This manuscript discusses the diagnostic evaluation of individuals with suspected breast cancer due to either abnormal imaging and/or physical fi...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Diagnosis and Management of High-Risk Breast Lesions.
Authors: Thomas PS Abstract Atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are nonmalignant breast lesions that confer a 4- to 10-fold increased risk for breast cancer in women. Often, AH and LCIS are diagnosed through breast biopsy due to a mammographic or palpable finding. Although AH and LCIS are benign breast disease, further management is necessary due to their high-risk nature and premalignant potential. Over the decades, management of AH and LCIS has changed as more is learned about these disease processes. This review explores the studies evaluating the risk for breast cancer in women with A...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position.
This article highlights NCCN's position on screening mammography and the screening controversy. PMID: 30442738 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Electronic Clinical Decision Tools for Improving Adherence to Colon Cancer Surveillance Guidelines: Can the Chips Finally Fall Into Place?
Authors: Peter S PMID: 30442739 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 19, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

One Size Fits All? Really?
Authors: Tempero M PMID: 30323084 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Shades of Survivorship.
Authors: Park ER, Peppercorn J, El-Jawahri A PMID: 30323085 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.
This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a BRAF p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib. During his response interval, new data emerged to justify subsequent treatment with both an immune checkpoint inhibitor and androgen blockade after his disease progressed. To our knowledge, this is the first report of frontline BRAF-directed therapy eliciting a response in metastatic SDC. PMID: 30323086 [PubMed - in process] (Source: Journal of the National Comprehens...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.
Authors: Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M Abstract The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

A Routine Laboratory Data-Based Model for Predicting Recurrence After Curative Resection of Stage II Colorectal Cancer.
Conclusions: A routine laboratory variable-based model may help predict DFS of patients with stage II CRC and identify high-risk patients more likely to benefit from chemotherapy. PMID: 30323088 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience.
Conclusions: Gemcitabine/platinum seems to be a superior regimen for patients with cHCC-CCA who require systemic treatment. Further studies are needed to clarify the regimen's efficacy and applicability in patient subgroups. PMID: 30323089 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora.
Conclusions: Dermatologic or mucosal conditions that might affect barrier integrity and use of corticosteroids and intravenous antibiotics prior to chemotherapy may increase risk of FN and should be considered in prophylaxis use and FN prediction modeling. PMID: 30323090 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Tumor Board Conferences for Multidisciplinary Skin Cancer Management: A Survey of US Cancer Centers.
Conclusions: Results showed overall consistency in meeting structure but variability in function, which may be a reflection of institutional resources and investment in the conference. Future directions include defining metrics to evaluate changes in diagnosis or management plan after tumor board discussion, attendance, clinical trial enrollment, and cost analysis. Results of this survey may aid other institutions striving to develop and refine skin cancer TBCs. PMID: 30323091 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Authors: Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Pirl W, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA Abstract The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common physical and psychosocial consequences of cancer and cancer treatment to help healthcare...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Preventive Health in Cancer Survivors: What Should We Be Recommending?
Authors: Overholser LS, Callaway C Abstract Individuals with a history of cancer, often referred to as cancer survivors, may experience late and long-term effects of their treatment. Because these individuals live longer in the survivorship phase, some of these late effects may also be considered risk factors for other chronic conditions. With cancer and cardiovascular disease now the top 2 leading causes of death in the United States and with common risk factors for both, as well as the morbidity that can occur after cancer treatment, preventive health is becoming an important issue in cancer survivorship care. Mu...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Immune Checkpoint Inhibitor Therapy in Breast Cancer.
Authors: Santa-Maria CA, Nanda R Abstract Initial studies investigating single-agent activity of immune checkpoint inhibitors (ICIs) serve as proof of principle that harnessing the immune system can have anticancer activity in a variety of human malignancies. Although breast cancer was historically believed to be immunogenically silent, early studies indicate overall response rates with ICIs are similar to those observed with many other solid malignancies. Overall response rates in advanced breast cancer are low, but the responses are remarkably durable. A deeper understanding of the biology of the interaction betw...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma.
Authors: Tsai FD, Haddad RI PMID: 30323095 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 17, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Getting What You Pay For: Finding Value in Cancer Care.
Authors: Tempero M PMID: 30181413 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Letter to the Editor: Significance of Clonal Hematopoiesis of Indeterminate Potential.
Authors: Sorscher S, Usha L, Burgess K, Klapko O, Buckingham L PMID: 30181414 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.
This report presents 2 patients with high-grade colorectal NECs who had different responses to treatment with combined BRAF/MEK inhibition after experiencing disease progression through first-line platinum-based chemotherapy. One patient experienced an excellent initial response to therapy before ultimately experiencing progression, and in the other patient initially had stable disease before eventually experiencing progression. These cases highlight the complicated role BRAF mutations play in gastrointestinal NECs, and the need for further research to identify not only patients who may benefit from BRAF-directed therapies...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Authors: Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA Abstract The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NC...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Use of Inpatient Palliative Care Services in Patients With Advanced Cancer Receiving Critical Care Therapies.
This study investigated the use pattern of IPC, outcomes (in-hospital mortality, length of stay [LOS], discharge destination, and cost of care), and predictors of IPC use in patients with metastatic cancer who received CCTs. We hypothesized that IPC services are underused in this cohort. Methods: In this retrospective cohort study, we used the 2010 California State Inpatient Databases to identify adults with metastatic cancer who received CCTs that are common and reliably coded (IMV, tracheostomy, percutaneous endoscopic gastrostomy tube, dialysis for acute kidney failure, and total parenteral nutrition). We determined IPC...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Ability to Predict New-Onset Psychological Distress Using Routinely Collected Health Data: A Population-Based Cohort Study of Women Diagnosed With Breast Cancer.
Conclusions: This study identified the predictors of new-onset psychological distress available in routinely collected administrative health databases, and showed how predictors change between hospital-based treatment and transitional survivorship periods. The results highlight the importance of developing predictive models tailored to the period of cancer care. PMID: 30181418 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Benchmarking Cancer Centers: From Care Pathways to Integrated Practice Units.
Conclusions: A benchmark tool for care pathways was successfully developed and tested, and is available in an open format. Our tool allows for the assessment of pathway organization and can be used to assess the status of IPU development. Opportunities for improvement were identified regarding the organization of care pathways and the development toward IPUs. Three centers are in varying degrees of implementation and can be characterized as breast cancer IPUs. Organizing cancer care in an IPU could yield multiple performance improvements. PMID: 30181419 [PubMed - in process] (Source: Journal of the National Comprehensi...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Conclusions: Despite a lack of survival benefit, concordant care was associated with lower costs, suggesting potential benefit to increasing standardization of care. These findings may influence policy decisions regarding implementation of pathway programs as health systems transition to value-based models. PMID: 30181420 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Chimeric Antigen Receptor T-Cell Therapy.
This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves. PMID: 30181421 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
Authors: Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H Abstract Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast pha...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 6, 2018 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research